{
  "id": "de0cbef2-2da2-4837-9f2f-44661a6135d0",
  "title": "Funding focus: Biotech dominates Netherlands’ top 10 rounds in H1 2025",
  "link": "https://thenextweb.com/news/funding-focus-biotech-dominates-netherlands-top-10-rounds-in-h1-2025",
  "description": "Funding focus is a new series analysing cash flow into the European tech ecosystem. After debuting with a look at the biggest rounds so far this year, we now turn to the largest deals in the Netherlands for H1. Startups in the Netherlands raised just $503mn (€429mn) in the first quarter of this year — the lowest quarterly total since the early days of the COVID-19 pandemic, according to Dealroom data. But three months later, the outlook has improved. Total funding for the first half of 2025 hit $1.4bn (€1.2bn). That’s down from $1.8bn (€1.54bn) at the same point last…This story continues at The Next Web",
  "author": "Siôn Geschwindt",
  "published": "Wed, 09 Jul 2025 07:00:10 +0000",
  "source": "https://thenextweb.com/feed/",
  "categories": [
    "Startups and technology",
    "Next Featured",
    "Ecosystems",
    "Investors and funding"
  ],
  "byline": "Siôn Geschwindt",
  "length": 3273,
  "excerpt": "Biotech startups made up half of the top 10 Dutch funding rounds in H1. Here’s the full list.",
  "siteName": "TNW | Ecosystems",
  "favicon": "https://next.tnwcdn.com/assets/img/favicon/favicon-194x194.png",
  "text": "Funding focus is a new series analysing cash flow into the European tech ecosystem. After debuting with a look at the biggest rounds so far this year, we now turn to the largest deals in the Netherlands for H1. Startups in the Netherlands raised just $503mn (€429mn) in the first quarter of this year — the lowest quarterly total since the early days of the COVID-19 pandemic, according to Dealroom data. But three months later, the outlook has improved. Total funding for the first half of 2025 hit $1.4bn (€1.2bn). That’s down from $1.8bn (€1.54bn) at the same point last year, but up from $1.1bn (€940) in H1 2023. The rebound was driven by a much stronger second quarter, during which startups secured $856mn (€940mn) — a 70% jump from Q1. Leading the momentum is biotech, with half of the top 10 funding rounds in H1 coming from startups with a grounding in the life sciences. Here’s the full list. 1.Azafaros — €132M  HQ: Leiden  Azafaros develops small-molecule drugs targeting rare metabolic disorders. The company raised €132mn in a Series B round in June 2025. 2. Finom — €115M HQ: Amsterdam  Finom operates a pan-European neobank for SMEs and entrepreneurs. It raised a €115mn Series C in June, following a €50mn Series B round the previous year.   3. Mews — €64M HQ: Amsterdam  Hospitality platform Mews secured $75mn (€64mn) in March. In total, Mews has bagged over $500mn (€425mn) to date, making it one of the Netherlands’ best-funded scaleups. 4. Toloka — €62M HQ: Amsterdam  Toloka is a crowdsourcing platform that uses a global network of human workers to label and evaluate data — text, images, audio, and more — for training and improving AI models. The business is part of Dutch AI infrastructure company Nebius.  In May, Toloka raised $72mn (€62mn) in a funding round led by Jeff Bezos’ investment firm, Bezos Expeditions. 5. Leyden Labs — €60M HQ: Leiden Leyden Labs is developing intranasal medicines to protect against respiratory viruses. In January, it raised $70mn (€60mn), bringing its total raised to $257mn (€220mn).  6. Alesta Therapeutics — €56M HQ: Leiden Alesta Therapeutics is another biotech startup from Leiden — home to one of Europe’s leading life science hubs. The company focuses on developing small-molecule therapies for rare diseases, which are taken orally. In January, it raised $65mn (€56mn) in Series A funding.   7. Salvia BioElectronics — €53M  HQ: Eindhoven Salvia BioElectronics makes soft brain implants to treat chronic migraines using gentle electrical pulses. In May, the startup raised €53mn in Series B funding. 8. Avidicure —  €44M HQ: Amsterdam Avidicure develops antibody therapies to activate the immune system and treat cancer. In April, it raised a hefty €44mn seed round to accelerate R\u0026D.    9. Piano — €38M HQ: Amsterdam Piano offers tools that help businesses understand their customers’ online behaviour and deliver personalised content or offers to keep them engaged and increase sales. In February, it raised $45mn (€38mn) in Series D funding.  10. Vivici — €32.5M Vivici is a foodtech startup using precision fermentation to produce animal-free dairy proteins. Its proteins are designed to replace traditional dairy ingredients like whey and casein. In February, it raised €32.5m in Series A funding.",
  "image": "https://img-cdn.tnwcdn.com/image/tnw-blurple?filter_last=1\u0026fit=1280%2C640\u0026url=https%3A%2F%2Fcdn0.tnwcdn.com%2Fwp-content%2Fblogs.dir%2F1%2Ffiles%2F2024%2F05%2FUntitled-design-1.jpg\u0026signature=466e7e4a6943cb561ecbf744135b01e0",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv id=\"article-main-content\"\u003e\n                            \n\u003cp\u003e\u003cem\u003eFunding focus is a new series analysing cash flow into the European tech ecosystem. After debuting with a look at \u003ca href=\"https://thenextweb.com/news/europes-20-largest-startup-funding-rounds-this-year-so-far\" target=\"_blank\" rel=\"noopener\"\u003ethe biggest rounds so far this year\u003c/a\u003e, we now turn to the largest deals in the Netherlands for H1.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eStartups in the Netherlands raised just $503mn (€429mn) in the first quarter of this year — the lowest quarterly total since the early days of the COVID-19 pandemic, according to Dealroom data. But three months later, the outlook has improved.\u003c/p\u003e\n\u003cp\u003eTotal funding for the first half of 2025 hit $1.4bn (€1.2bn). That’s down from $1.8bn (€1.54bn) at the same point last year, but up from $1.1bn (€940) in H1 2023.\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eThe rebound was driven by a much stronger second quarter, during which startups secured $856mn (€940mn) — a 70% jump from Q1.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eLeading the momentum is biotech, with half of the top 10 funding rounds in H1 coming from startups with a grounding in the life sciences. Here’s the full list.\u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e1.Azafaros — €132M \u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Leiden \u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eAzafaros develops small-molecule drugs targeting rare metabolic disorders. The company raised €132mn in a Series B round in June 2025.\u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e2. Finom\u003c/b\u003e \u003cb\u003e—\u003c/b\u003e \u003cb\u003e€115M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Amsterdam \u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eFinom operates a pan-European neobank for SMEs and entrepreneurs. It raised a \u003c/span\u003e\u003cspan\u003e€115mn Series C in June, following a €50mn \u003c/span\u003e\u003ca href=\"https://thenextweb.com/news/fintech-finom-funding-digital-banking-smes\" target=\"_blank\" rel=\"noopener\"\u003e\u003cspan\u003eSeries B round\u003c/span\u003e\u003c/a\u003e\u003cspan\u003e the previous year.  \u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e3. Mews\u003c/b\u003e \u003cb\u003e—\u003c/b\u003e \u003cb\u003e€64M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Amsterdam \u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eHospitality platform Mews\u003c/span\u003e\u003cspan\u003e secured $75mn (\u003c/span\u003e\u003cspan\u003e€64mn)\u003c/span\u003e \u003cspan\u003ein March. \u003c/span\u003e\u003cspan\u003eIn total, Mews has bagged over $500mn (\u003c/span\u003e\u003cspan\u003e€425mn)\u003c/span\u003e\u003cspan\u003e to date, making it one of the Netherlands’ best-funded scaleups.\u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e4. Toloka\u003c/b\u003e\u003cspan\u003e — \u003c/span\u003e\u003cb\u003e€62M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Amsterdam \u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eToloka is a crowdsourcing platform that uses a global network of human workers to label and evaluate data — text, images, audio, and more — for training and improving AI models. \u003c/span\u003e\u003cspan\u003eThe business is part of Dutch AI infrastructure company \u003c/span\u003e\u003ca href=\"https://thenextweb.com/news/nvidia-accel-nebius-ai-chip-funding-700-million\" target=\"_blank\" rel=\"noopener\"\u003e\u003cspan\u003eNebius\u003c/span\u003e\u003c/a\u003e\u003cspan\u003e. \u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eIn May, Toloka raised $72mn (\u003c/span\u003e\u003cspan\u003e€62mn) in a funding round led by Jeff Bezos’ investment firm, Bezos Expeditions.\u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e5. Leyden Labs\u003c/b\u003e\u003cspan\u003e — \u003c/span\u003e\u003cb\u003e€60M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Leiden\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eLeyden Labs is developing intranasal medicines to protect against respiratory viruses. In January, it raised $70mn (€60mn), bringing its total raised to \u003c/span\u003e\u003cspan\u003e$257mn (\u003c/span\u003e\u003cspan\u003e€220mn).\u003c/span\u003e\u003cspan\u003e \u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e6. Alesta Therapeutics — \u003c/b\u003e\u003cb\u003e€56M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Leiden\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eAlesta Therapeutics is another biotech startup from Leiden — home to one of Europe’s leading life science hubs. The company focuses on developing small-molecule therapies for rare diseases, which are taken orally. In January, it raised \u003c/span\u003e\u003cspan\u003e$65mn (\u003c/span\u003e\u003cspan\u003e€56mn) in Series A funding. \u003c/span\u003e\u003cspan\u003e \u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e7. Salvia BioElectronics — \u003c/b\u003e\u003cb\u003e€53M\u003c/b\u003e\u003cb\u003e \u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Eindhoven\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eSalvia BioElectronics makes soft brain implants to treat chronic migraines using gentle electrical pulses. In May, the startup raised \u003c/span\u003e\u003cspan\u003e€53mn in Series B funding.\u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e8. Avidicure —  \u003c/b\u003e\u003cb\u003e€\u003c/b\u003e\u003cb\u003e44M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Amsterdam\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003eAvidicure develops antibody therapies to activate the immune system and treat cancer. In April, it raised a hefty €44mn seed round to accelerate R\u0026amp;D.   \u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e9. Piano — \u003c/b\u003e\u003cb\u003e€\u003c/b\u003e\u003cb\u003e38M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cspan\u003eHQ: Amsterdam\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan\u003ePiano offers tools that help businesses understand their customers’ online behaviour and deliver personalised content or offers to keep them engaged and increase sales. In February, it raised $45mn (€38mn) in Series D funding. \u003c/span\u003e\u003c/p\u003e\n\u003ch3\u003e\u003cb\u003e10. Vivici — €32.5M\u003c/b\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cb\u003e\u003c/b\u003e\u003cspan\u003eVivici is a foodtech startup using precision fermentation to produce animal-free dairy proteins. Its proteins are designed to replace traditional dairy ingredients like whey and casein. In February, it raised \u003c/span\u003e\u003cspan\u003e€32.5m in Series A funding. \u003c/span\u003e\u003c/p\u003e\n                        \u003c/div\u003e\u003c/div\u003e",
  "readingTime": "4 min read",
  "publishedTime": "2025-07-09T07:00:10Z",
  "modifiedTime": "2025-07-09T10:35:19Z"
}
